Kane identifies lead candidate for coating central venous catheters

By Elaine Rigoli

Tampa, Fla., Aug. 24 - Kane Biotech, Inc. said it has identified a coating product, identified as KBI-4258, for reducing infections associated with central venous catheters.

"The selection of KBI-4258 is another important step for Kane as we develop a pipeline of products that leverage our expertise in the prevention of bacterial biofilms. The effects of this composition have been impressive in the laboratory, and we therefore enter the next steps for this product with great enthusiasm," president Gord Froehlich said in a news release.

Kane is a biotechnology company based in Winnipeg, Man.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.